Biogen’s Newly Approved Alzheimer’s Drug Ships in 2 Weeks. The Confirmatory Trial Will Take 8 Years.
source: pixabay.com

Biogen’s Newly Approved Alzheimer’s Drug Ships in 2 Weeks. The Confirmatory Trial Will Take 8 Years.

  The pressure was on. Researchers had been studying Alzheimer’s for decades. Every morsel of discovery was hailed as moving closer to a cure and results were always expected soon…

Continue Reading Biogen’s Newly Approved Alzheimer’s Drug Ships in 2 Weeks. The Confirmatory Trial Will Take 8 Years.
FDA Approves New Alzheimer’s Drug, But Not Without Controversy
source: pixabay.com

FDA Approves New Alzheimer’s Drug, But Not Without Controversy

According to an announcement from the US Food and Drug Administration (FDA), the agency has recently approved a new therapy for Alzheimer's disease. While this is a significant moment for…

Continue Reading FDA Approves New Alzheimer’s Drug, But Not Without Controversy

Light Therapy: A Safe, Effective, and Low-Cost Approach to Some Neurodegenerative Diseases

In the last decade, scientists have made great strides in uncovering details of the underlying causes of neurodegenerative diseases. It is only a matter of time that treatment and prevention…

Continue Reading Light Therapy: A Safe, Effective, and Low-Cost Approach to Some Neurodegenerative Diseases
LX1001 for APOE4-Associated Alzheimer’s Granted Fast Track Designation
Thor_Deichmann / Pixabay

LX1001 for APOE4-Associated Alzheimer’s Granted Fast Track Designation

  In a recent press release, biotechnology and gene therapy company LEXEO Therapeutics ("LEXEO") shared that its gene therapy LX1001 received Fast Track designation from the FDA. Overall, LX1001 is…

Continue Reading LX1001 for APOE4-Associated Alzheimer’s Granted Fast Track Designation
A First: Human Clinical Trial Assessing Gene Therapy for Alzheimer’s Disease
source: pixabay.com

A First: Human Clinical Trial Assessing Gene Therapy for Alzheimer’s Disease

Billions of dollars have been spent in research over decades, resulting in only two therapies that treat symptoms of Alzheimer’s disease (AD). There are no approved methods that diminish the…

Continue Reading A First: Human Clinical Trial Assessing Gene Therapy for Alzheimer’s Disease
Five Genes Identified That May Cause Lewy Body Dementia
source: pixabay.com

Five Genes Identified That May Cause Lewy Body Dementia

According to a recent press release, scientists studying the Uniformed Services University of the Health Sciences' (USU) The American Genome Center (TAGC) identified five genes which could play a role…

Continue Reading Five Genes Identified That May Cause Lewy Body Dementia
Each New Discovery Brings Scientists Closer to Finding the Cause of Alzheimer’s Disease
source: pixabay.com

Each New Discovery Brings Scientists Closer to Finding the Cause of Alzheimer’s Disease

Scientists are researching Alzheimer’s disease (AD) from all angles and gradually closing in on the cause of the disease. According to an article in Neuroscience News, a discovery by researchers…

Continue Reading Each New Discovery Brings Scientists Closer to Finding the Cause of Alzheimer’s Disease
Neuroscientists Are Focusing on Synthetic Pharmaceuticals to Restore Cognitive Function in Alzheimer’s Disease
source: pixabay.com

Neuroscientists Are Focusing on Synthetic Pharmaceuticals to Restore Cognitive Function in Alzheimer’s Disease

Improving cognition and identifying abnormal molecular pathways in Alzheimer’s disease has been challenging. Current studies of Alzheimer’s disease have focused on reducing such occurrences as amyloid plaque, neuroinflammation, and neurofibrillary…

Continue Reading Neuroscientists Are Focusing on Synthetic Pharmaceuticals to Restore Cognitive Function in Alzheimer’s Disease
Discovery of Three Molecular Subtypes Brings Us Closer to Unraveling Alzheimer’s Disease
source: pixabay.com

Discovery of Three Molecular Subtypes Brings Us Closer to Unraveling Alzheimer’s Disease

  There are many common elements in Alzheimer’s disease (AD), which is the most common type of dementia. It is now evident that there are varied spans of disease progression…

Continue Reading Discovery of Three Molecular Subtypes Brings Us Closer to Unraveling Alzheimer’s Disease
These Alzheimer’s Patients Keep Their Memory
source: pixabay.com

These Alzheimer’s Patients Keep Their Memory

As reported in Newswise; 40% of people with primary progressive aphasia, a rare neurological disorder causing progressive language loss, also have underlying Alzheimer’s disease. However, while Alzheimer’s disease is characterized…

Continue Reading These Alzheimer’s Patients Keep Their Memory

Why The FDA Cautions Rare Neurological Disease Patients About Dental Amalgams

In a press release from the FDA; the FDA has new recommendations for a common mercury-based filling, dental amalgams. While the mercury in the tooth treatment isn't significant enough to…

Continue Reading Why The FDA Cautions Rare Neurological Disease Patients About Dental Amalgams
New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life
source: pixabay.com

New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life

Dilated cardiomyopathy is a heart condition caused by a mutation in the RBM20 gene. This heart condition is unique because it can affect young adults. These individuals are at an…

Continue Reading New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life
Researchers Have Discovered a New Molecular Mechanism in Alzheimer’s Disease
Sourced from publicdomainpictures.net (https://www.publicdomainpictures.net/en/view-image.php?image=275669&picture=chemical-research)

Researchers Have Discovered a New Molecular Mechanism in Alzheimer’s Disease

At the Tufts University School of Medicine, researchers have uncovered a molecular mechanism that eventually leads to a build-up of amyloid beta, which is a major cause of Alzheimer's disease.…

Continue Reading Researchers Have Discovered a New Molecular Mechanism in Alzheimer’s Disease
EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment
stevepb / Pixabay

EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment

The European Medicines Agency has accepted Biogen's Marketing Authorization Application (MAA) for review. The application is for aducanumab, a treatment for Alzheimer's disease. As this condition faces an unmet medical…

Continue Reading EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment
New Research Will Target Tau’s Role in Alzheimer’s Disease
source: pixabay.com

New Research Will Target Tau’s Role in Alzheimer’s Disease

Researchers from Rensselaer Polytechnic Institute have been conducting research on tau proteins, specifically how it spreads from cell to cell. According to an article in Newswise, this team of researchers…

Continue Reading New Research Will Target Tau’s Role in Alzheimer’s Disease

Could TKIs Be Effective for Patients with Alzheimer’s, Parkinson’s, and Dementia?

What sort of treatments are available for patients with dementia and other neurodegenerative conditions? Are these treatments safe and effective? While these questions vary in answers, researchers are currently exploring…

Continue Reading Could TKIs Be Effective for Patients with Alzheimer’s, Parkinson’s, and Dementia?

Until COVID-19 Disrupted our Lives, Alzheimer’s Disease Was Considered the Greatest Medical Challenge of the Century

Many different approaches have been offered by scientists to stem the overwhelming tide of Alzheimer’s disease (AD). Fifty percent of primary care physicians believe that the medical profession is not…

Continue Reading Until COVID-19 Disrupted our Lives, Alzheimer’s Disease Was Considered the Greatest Medical Challenge of the Century
First Patient with Alzheimer’s Dosed in Bryostatin-1 Clinical Trial
source: pixabay.com

First Patient with Alzheimer’s Dosed in Bryostatin-1 Clinical Trial

  Last week, clinical stage biopharmaceutical company Neurotrope announced that the first patient was dosed in a Phase 2 clinical trial to test the safety, efficacy, and tolerability of bryostatin-1…

Continue Reading First Patient with Alzheimer’s Dosed in Bryostatin-1 Clinical Trial
Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
source: pixabay.com

Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases

  According to a recent article in Business Wire, it is estimated that five million people in the United States over the age of sixty-five are coping with Alzheimer’s at…

Continue Reading Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases